Literature DB >> 26506264

p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.

Carwyn Davies1,2, Linda A Hogarth3, Karen L Mackenzie1, Andrew G Hall3, Richard B Lock1.   

Abstract

p21(WAF1) is a well-characterized mediator of cell cycle arrest and may also modulate chemotherapy-induced cell death. The role of p21(WAF1) in drug-induced cell cycle arrest and apoptosis of acute lymphoblastic leukemia (ALL) cells was investigated using p53-functional patient-derived xenografts (PDXs), in which p21(WAF1) was epigenetically silenced in T-cell ALL (T-ALL), but not in B-cell precursor (BCP)-ALL PDXs. Upon exposure to diverse cytotoxic drugs, T-ALL PDX cells exhibited markedly increased caspase-3/7 activity and phosphatidylserine (PS) externalization on the plasma membrane compared with BCP-ALL cells. Despite dramatic differences in apoptotic characteristics between T-ALL and BCP-ALL PDXs, both ALL subtypes exhibited similar cell death kinetics and were equally sensitive to p53-inducing drugs in vitro, although T-ALL PDXs were significantly more sensitive to the histone deacetylase inhibitor vorinostat. Transient siRNA suppression of p21(WAF1) in the BCP-ALL 697 cell line resulted in a moderate depletion of the cell fraction in G1 phase and marked increase in PS externalization following exposure to etoposide. Furthermore, stable lentiviral p21(WAF1) silencing in the BCP-ALL Nalm-6 cell line accelerated PS externalization and cell death following exposure to etoposide and vorinostat, supporting previous findings. Finally, the Sp1 inhibitor, terameprocol, inhibited p21(WAF1) expression in Nalm-6 cells exposed to vorinostat and also partially augmented vorinostat-induced cell death. Taken together, these findings demonstrate that p21(WAF1) regulates the early stages of drug-induced apoptosis in ALL cells and significantly modulates their sensitivity to vorinostat.

Entities:  

Keywords:  childhood acute lymphoblastic leukemia; etoposide; p21WAF1; patient derived xenograft models; terameprocol; vorinostat

Mesh:

Substances:

Year:  2015        PMID: 26506264      PMCID: PMC4825786          DOI: 10.1080/15384101.2015.1100774

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  57 in total

1.  Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia.

Authors:  O Blau; S Avigad; B Stark; Y Kodman; D Luria; I J Cohen; R Zaizov
Journal:  Leuk Res       Date:  1997-08       Impact factor: 3.156

Review 2.  Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues.

Authors:  Christopher D Gregory; John D Pound
Journal:  J Pathol       Date:  2010-10-25       Impact factor: 7.996

3.  Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells.

Authors:  J Wendt; S Radetzki; C von Haefen; P G Hemmati; D Güner; K Schulze-Osthoff; B Dörken; P T Daniel
Journal:  Oncogene       Date:  2006-02-16       Impact factor: 9.867

4.  Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia.

Authors:  L A Hogarth; A G Hall
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

5.  p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis.

Authors:  H Tian; E K Wittmack; T J Jorgensen
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

6.  Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression.

Authors:  Chih-Chuan Chang; Jonathan D Heller; Jennifer Kuo; Ru Chih C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.

Authors:  Santi Suryani; Hernan Carol; Triona Ni Chonghaile; Viktoras Frismantas; Chintanu Sarmah; Laura High; Beat Bornhauser; Mark J Cowley; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Elise Tonna; Luke Jones; Donya Moradi Manesh; Raushan T Kurmasheva; Catherine Billups; Warren Kaplan; Anthony Letai; Jean-Pierre Bourquin; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2014-07-10       Impact factor: 12.531

8.  Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Authors:  Hernan Carol; Richard Gorlick; E Anders Kolb; Christopher L Morton; Donya Moradi Manesh; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Amy Wozniak; Ian Hickson; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard Lock
Journal:  Pediatr Blood Cancer       Date:  2013-09-04       Impact factor: 3.167

9.  Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio.

Authors:  Delphine Javelaud; Francoise Besancon
Journal:  J Biol Chem       Date:  2002-07-31       Impact factor: 5.157

10.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more
  2 in total

1.  AKT is indispensable for coordinating Par-4/JNK cross talk in p21 downmodulation during ER stress.

Authors:  R U Rasool; D Nayak; S Chakraborty; M M Faheem; B Rah; P Mahajan; V Gopinath; A Katoch; Z Iqra; S K Yousuf; D Mukherjee; L D Kumar; A Nargotra; A Goswami
Journal:  Oncogenesis       Date:  2017-05-22       Impact factor: 7.485

2.  Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.

Authors:  Ewa Jasek-Gajda; Halina Jurkowska; Małgorzata Jasińska; Jan A Litwin; Grzegorz J Lis
Journal:  Apoptosis       Date:  2019-12       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.